|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPS16 |
Gene summary for RPS16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPS16 | Gene ID | 6217 |
| Gene name | ribosomal protein S16 | |
| Gene Alias | S16 | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000462 | UniProtAcc | P62249 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6217 | RPS16 | GSM4909281 | Human | Breast | IDC | 1.93e-12 | 1.87e-01 | 0.21 |
| 6217 | RPS16 | GSM4909282 | Human | Breast | IDC | 7.81e-09 | -1.23e-01 | -0.0288 |
| 6217 | RPS16 | GSM4909285 | Human | Breast | IDC | 3.98e-80 | 4.09e-01 | 0.21 |
| 6217 | RPS16 | GSM4909286 | Human | Breast | IDC | 1.41e-43 | 2.84e-01 | 0.1081 |
| 6217 | RPS16 | GSM4909288 | Human | Breast | IDC | 1.83e-03 | 1.21e-01 | 0.0988 |
| 6217 | RPS16 | GSM4909290 | Human | Breast | IDC | 4.28e-14 | 1.91e-01 | 0.2096 |
| 6217 | RPS16 | GSM4909291 | Human | Breast | IDC | 4.48e-17 | 2.04e-01 | 0.1753 |
| 6217 | RPS16 | GSM4909293 | Human | Breast | IDC | 3.81e-18 | -1.39e-01 | 0.1581 |
| 6217 | RPS16 | GSM4909294 | Human | Breast | IDC | 4.39e-15 | 1.52e-01 | 0.2022 |
| 6217 | RPS16 | GSM4909296 | Human | Breast | IDC | 5.83e-13 | 1.73e-01 | 0.1524 |
| 6217 | RPS16 | GSM4909297 | Human | Breast | IDC | 1.87e-03 | -1.23e-01 | 0.1517 |
| 6217 | RPS16 | GSM4909298 | Human | Breast | IDC | 2.48e-06 | 1.50e-01 | 0.1551 |
| 6217 | RPS16 | GSM4909302 | Human | Breast | IDC | 5.81e-10 | 1.08e-01 | 0.1545 |
| 6217 | RPS16 | GSM4909304 | Human | Breast | IDC | 5.30e-04 | 1.53e-01 | 0.1636 |
| 6217 | RPS16 | GSM4909307 | Human | Breast | IDC | 3.41e-06 | 1.49e-01 | 0.1569 |
| 6217 | RPS16 | GSM4909311 | Human | Breast | IDC | 4.25e-16 | -2.47e-02 | 0.1534 |
| 6217 | RPS16 | GSM4909315 | Human | Breast | IDC | 1.06e-03 | 9.42e-02 | 0.21 |
| 6217 | RPS16 | GSM4909319 | Human | Breast | IDC | 1.04e-24 | -2.35e-01 | 0.1563 |
| 6217 | RPS16 | GSM4909320 | Human | Breast | IDC | 2.15e-03 | 1.35e-01 | 0.1575 |
| 6217 | RPS16 | brca2 | Human | Breast | Precancer | 1.33e-30 | -2.06e-01 | -0.024 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00610087 | Liver | NAFLD | hepaticobiliary system development | 38/1882 | 150/18723 | 5.94e-08 | 5.42e-06 | 38 |
| GO:00018897 | Liver | NAFLD | liver development | 37/1882 | 147/18723 | 1.06e-07 | 8.12e-06 | 37 |
| GO:00226137 | Liver | NAFLD | ribonucleoprotein complex biogenesis | 76/1882 | 463/18723 | 1.19e-05 | 3.67e-04 | 76 |
| GO:00311003 | Liver | NAFLD | animal organ regeneration | 20/1882 | 76/18723 | 4.33e-05 | 1.06e-03 | 20 |
| GO:00422547 | Liver | NAFLD | ribosome biogenesis | 52/1882 | 299/18723 | 6.03e-05 | 1.32e-03 | 52 |
| GO:00422747 | Liver | NAFLD | ribosomal small subunit biogenesis | 19/1882 | 73/18723 | 7.85e-05 | 1.61e-03 | 19 |
| GO:00487327 | Liver | NAFLD | gland development | 67/1882 | 436/18723 | 2.83e-04 | 4.53e-03 | 67 |
| GO:00310993 | Liver | NAFLD | regeneration | 35/1882 | 198/18723 | 6.67e-04 | 8.61e-03 | 35 |
| GO:00974215 | Liver | NAFLD | liver regeneration | 10/1882 | 35/18723 | 1.79e-03 | 1.85e-02 | 10 |
| GO:00344704 | Liver | NAFLD | ncRNA processing | 57/1882 | 395/18723 | 3.34e-03 | 2.93e-02 | 57 |
| GO:00063644 | Liver | NAFLD | rRNA processing | 35/1882 | 225/18723 | 6.04e-03 | 4.54e-02 | 35 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:000636412 | Liver | Cirrhotic | rRNA processing | 115/4634 | 225/18723 | 1.12e-17 | 1.64e-15 | 115 |
| GO:00160724 | Liver | Cirrhotic | rRNA metabolic process | 119/4634 | 236/18723 | 1.19e-17 | 1.70e-15 | 119 |
| GO:000188912 | Liver | Cirrhotic | liver development | 81/4634 | 147/18723 | 2.99e-15 | 3.35e-13 | 81 |
| GO:006100812 | Liver | Cirrhotic | hepaticobiliary system development | 82/4634 | 150/18723 | 3.72e-15 | 4.09e-13 | 82 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| GO:004227412 | Liver | Cirrhotic | ribosomal small subunit biogenesis | 42/4634 | 73/18723 | 2.34e-09 | 9.73e-08 | 42 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPS16 | SNV | Missense_Mutation | c.139C>G | p.Leu47Val | p.L47V | P62249 | protein_coding | deleterious(0.02) | probably_damaging(0.926) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| RPS16 | SNV | Missense_Mutation | novel | c.176N>A | p.Gly59Asp | p.G59D | P62249 | protein_coding | deleterious(0.03) | possibly_damaging(0.686) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPS16 | SNV | Missense_Mutation | novel | c.254G>A | p.Arg85His | p.R85H | P62249 | protein_coding | deleterious(0.02) | possibly_damaging(0.907) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPS16 | SNV | Missense_Mutation | c.163G>A | p.Val55Ile | p.V55I | P62249 | protein_coding | tolerated(0.73) | benign(0.029) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPS16 | SNV | Missense_Mutation | novel | c.206N>A | p.Arg69His | p.R69H | P62249 | protein_coding | tolerated(0.05) | benign(0.106) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPS16 | SNV | Missense_Mutation | novel | c.253N>T | p.Arg85Cys | p.R85C | P62249 | protein_coding | deleterious(0.04) | possibly_damaging(0.797) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPS16 | SNV | Missense_Mutation | novel | c.49N>G | p.Lys17Glu | p.K17E | P62249 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPS16 | SNV | Missense_Mutation | c.346G>T | p.Asp116Tyr | p.D116Y | P62249 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| RPS16 | SNV | Missense_Mutation | novel | c.205N>T | p.Arg69Cys | p.R69C | P62249 | protein_coding | deleterious(0.04) | benign(0.294) | TCGA-77-A5GA-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |